ACR: Can Tanezumab Be Revived for OA? | Orthopedics 2019 | May 13 - 14, 2019 | Singapore

ACR: Can Tanezumab Be Revived for OA? Low incidence of rapidly progressive OA seen with lower doses

CHICAGO -- The monoclonal antibody tanezumab, which blocks nerve growth factor, showed significant benefits in pain and function among patients with osteoarthritis (OA) of the knee or hip, and rates of severe adverse joint events such as rapidly progressive OA that had plagued earlier studies were low, a researcher reported at the annual meeting of the American College of Rheumatology here.

Recent posts